Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Verve Therapeutics

Evaluate

Thumbnail
July 17, 2023

Sanofi goes back to Scribe

The latest deal focuses on in vivo Crispr editing for sickle cell disease, and follows last year’s cancer collaboration.

June 30, 2023

Big biotech's upcoming clinical priorities

Key catalysts lie ahead for Amgen, Argenx, Point Biopharma and Novo Nordisk.

Article image
Vantage logo
June 15, 2023

Lilly signs up Verve to take on Novartis and Amgen

Today’s $60m deal is focused on Lp(a), a new cardiovascular target for the gene editing company.

Article image
Vantage logo
May 23, 2023

EASC 2023 – Arrowhead takes on Regeneron in cholesterol lowering

Article image
Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

A new report from Evaluate Vantage looks at recent developments in gene editing and delivery.

Article image
Vantage logo
March 07, 2023

Merck leads the new cholesterol-lowering push

Article image
Vantage logo
March 06, 2023

ACC 2023 – Merck’s oral cholesterol lowerer shows mid-stage promise

The oral PCSK9 project MK-0616 meets its targets in phase 2, which could be bad news for Novartis.

Article image
Vantage logo
February 16, 2023

Why Verve investors might hope for hold resolution soon

Article image
Vantage logo
January 26, 2023

Xylocor sees enough to press on with angina gene therapy

A pivotal trial is in the works, but can the group succeed where other VEGF gene therapies have failed?

Article image
Vantage logo
January 06, 2023

Will Graphite's blow-up add to FDA caution over gene editing?

Article image
Vantage logo
November 07, 2022

Verve hit by FDA’s gene editing caution

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up